Y-mAbs Therapeutics, Inc.
YMAB
$4.73
-$0.18-3.67%
| Weiss Ratings | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.05 | |||
| Price History | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.64% | |||
| 30-Day Total Return | -23.09% | |||
| 60-Day Total Return | -51.59% | |||
| 90-Day Total Return | -68.15% | |||
| Year to Date Total Return | -40.65% | |||
| 1-Year Total Return | -70.14% | |||
| 2-Year Total Return | 38.30% | |||
| 3-Year Total Return | -45.51% | |||
| 5-Year Total Return | -77.47% | |||
| 52-Week High % Change | -72.38% | |||
| 52-Week Low % Change | 15.53% | |||
| Price | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $17.78 | |||
| 52-Week Low Price | $4.25 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | May 03, 2024 | |||
| Valuation | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 222.02M | |||
| Enterprise Value | 155.61M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.67 | |||
| Earnings Per Share Growth | 35.57% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.51 | |||
| Price/Book (Q) | 2.40 | |||
| Enterprise Value/Revenue (TTM) | 1.77 | |||
| Price | $4.73 | |||
| Enterprise Value/EBITDA (TTM) | -5.48 | |||
| Enterprise Value/EBIT | -5.38 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 44.88M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 885 8505 | |||
| Address | 230 Park Avenue New York, NY 10169 | |||
| Website | www.ymabs.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -32.97% | |||
| Profit Margin | -33.83% | |||
| Management Effectiveness | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -14.58% | |||
| Return on Equity | -- | |||
| Income Statement | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 87.69M | |||
| Total Revenue (TTM) | 87.69M | |||
| Revenue Per Share | $1.95 | |||
| Gross Profit (TTM) | 72.43M | |||
| EBITDA (TTM) | -28.38M | |||
| EBIT (TTM) | -28.91M | |||
| Net Income (TTM) | -29.67M | |||
| Net Income Avl. to Common (TTM) | -29.67M | |||
| Total Revenue Growth (Q YOY) | 13.41% | |||
| Earnings Growth (Q YOY) | -587.25% | |||
| EPS Diluted (TTM) | -0.67 | |||
| EPS Diluted Growth (Q YOY) | -573.01% | |||
| Balance Sheet | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 67.23M | |||
| Cash Per Share (Q) | $1.50 | |||
| Total Current Assets (Q) | 98.51M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 92.00M | |||
| Current Ratio (Q) | 4.157 | |||
| Book Value Per Share (Q) | $2.05 | |||
| Total Assets (Q) | 119.90M | |||
| Total Current Liabilities (Q) | 23.70M | |||
| Total Debt (Q) | 820.00K | |||
| Total Liabilities (Q) | 27.90M | |||
| Total Common Equity (Q) | 92.00M | |||
| Cash Flow | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 4.31M | |||
| Net Change in Cash (TTM) | -11.40M | |||
| Levered Free Cash Flow (TTM) | 2.07M | |||
| Cash from Operations (TTM) | -15.71M | |||
